Again, I’m all for anecdotal advocacy and the use of any drugs people prefer
I still don’t see the point of focusing on more dangerous, less effective drugs as therapy when we have a perfectly safe, effective therapy available.
Maybe I’m missing something from what you’re saying, because I didn’t see any outline for why maps is focusing on Molly specifically for PTSD.
The proposed benefits you’re talking about using Molly are already known benefits of taking psilocybin, athough psilocybin has a lower physiological risk and simpler therapy scheduling.
No problem with researching both, this is more a case of diagnosing a problem, having the solution, but making people wait by purposefully diverting our attention elsewhere while there is a more effective, risk-free solution available.
It seems at best a waste of time and at worst cruel to tell people we might decide to help them soon If they wait for unknown years while we look into different solutions instead of helping them directly at no risk with the safe, effective solution we have.